Loading...
Organogenesis Q1 2025 Earnings Report
Organogenesis Holdings Inc. reported a significant decrease in net revenue and a substantial increase in net loss for the first quarter of 2025 compared to the same period in 2024.
Key Takeaways
Organogenesis Holdings Inc. reported a net revenue of $86.7 million for the first quarter of 2025, a 21% decrease from $110.0 million in the prior year. The company experienced a net loss of $18.8 million, a significant increase from a net loss of $2.1 million in the first quarter of 2024. This decline was primarily driven by a 23% decrease in Advanced Wound Care product revenue.
Net revenue for Q1 2025 was $86.7 million, a 21% decrease from $110.0 million in Q1 2024.
Net loss for Q1 2025 was $18.8 million, an increase of $16.7 million from a net loss of $2.1 million in Q1 2024.
Advanced Wound Care product revenue decreased by 23% to $79.9 million, while Surgical & Sports Medicine product revenue increased by 11% to $6.8 million.
Adjusted EBITDA loss was $12.5 million for Q1 2025, a decrease of $15.1 million from an Adjusted EBITDA income of $2.6 million in Q1 2024.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.comSurgical & Sports Medicine Revenue
CapyFin.com Forward Guidance
For the year ending December 31, 2025, Organogenesis Holdings Inc. reaffirms its prior revenue guidance and updates its profitability guidance.
Positive Outlook
- Net revenue is projected to be between $480.0 million and $535.0 million, representing a year-over-year change in the range of roughly flat to an increase of 11%.
- Net revenue from Advanced Wound Care products is expected to be between $450.0 million and $500.0 million, a decrease of 1% to an increase of 10% year-over-year.
- Net revenue from Surgical & Sports Medicine products is expected to be between $30.0 million and $35.0 million, an increase of 6% to 23% year-over-year.
- Net income is projected to be between $4.7 million and $34.0 million.
- Adjusted net income is projected to be between $15.3 million and $44.6 million.
Challenges Ahead
- The guidance for Advanced Wound Care products includes a potential decrease of 1% year-over-year.
- The company acknowledges a challenging market and evolving reimbursement landscape.
- The guidance for net income and adjusted net income still presents a wide range, indicating potential variability.
- The company's ability to obtain regulatory approval for and successfully commercialize ReNu is a risk.
- The impact and uncertainty of any changes to the coverage and reimbursement levels for the Company's products (including as a result of proposed LCDs that could take effect as soon as January 1, 2026) could adversely affect the business.
Revenue & Expenses
Visualization of income flow from segment revenue to net income